Compare Brookfield Infrastructure Partners LP (BIP) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs BioNTech SE - ADR — how do they compare? Brookfield Infrastructure Partners LP trades at $39.54 (market cap $18.10B), while BioNTech SE - ADR trades at $92.94 (market cap $23.31B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and Brookfield Infrastructure Partners LP pays a 4.62% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BIP | BNTX | |
|---|---|---|
Market Cap | $18.10B | $23.31B |
Sector | Industrials | Health |
52-Week High | $42.62 | $119.34 |
52-Week Low | $29.81 | $83.89 |
Enterprise Value | $77.05B | $6.60B |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.55, up 4.13% in the last session, with a bullish technical signal and strong analyst support. Recent earnings misses contrast with positive cash flow trends and a 6.97 EV/EBITDA valuation. News highlights dividend appeal and corporate simplification efforts, while institutional interest remains robust.
Outlook is cautiously optimistic given high analyst buy ratings and a $44.67 price target, but risks include earnings volatility and margin pressure. The stock offers income potential with dividends, though net income declined to $652M in 2026. Investors should weigh solid infrastructure assets against execution challenges.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
